On June 20th, 2023, Relief Therapeutics proudly invites its shareholders to its Annual General Meeting held at the gorgeous avenue de Sécheron 15 in Geneva, in the very vicinity of the company’s offices. This meeting promises exquisite information on the innovative treatment options and transformative outcomes proposed to help those suffering from select specialty and rare diseases, offering a unique industry-leading opportunity. Don’t miss your chance to get ahead of the game and join Relief Therapeutics in ushering a healthier future for everyone!
At the upcoming general meeting, the shareholders will be asked to review and approve the annual accounts for the 2022 financial year, appropriate the result, give a discharge to the board of directors and executive committee for their duties performed in 2022, extend the duration of the Company’s capital band and increase the conditional share capital.
Additionally, various proposed amendments and addition to the articles of association related to the new Swiss corporate law will be discussed. Furthermore, the company will make decisions regarding the compensation of members of the board of directors and executive committee, and voting for the re-election of the current board of directors, the chairman of the board of directors, the nomination and compensation committee, the independent voting rights representative and the auditors.
We invite all our esteemed shareholders to join us at the upcoming Annual General Meeting (AGM), where we will provide all the details of attending the meeting in person or by proxy, our requirements for notification and registration, and an overview of our e-voting system. All relevant documents for the meeting will be sent out on Tues., May 30, 2023. Don’t miss this opportunity to be a part of the decision-making process!
ABOUT RELIEF THERAPEUTICS
At Relief Therapeutics, we are committed to improving lives and making a difference in the lives of patients suffering from select specialty and rare diseases. Through our pioneering Physiomimic™ and TEHCLO™ drug delivery platform technologies, and an extensive clinical development pipeline focusing on rare metabolic disorders, rare skin diseases and rare respiratory diseases, we are delivering therapies that offer greater efficacy, safety and convenience.
Our team is comprised of experienced biopharma professionals with a deep understanding of research, development, and rare diseases – all working towards providing therapeutic relief to those in need. Relief Therapeutics is headquartered in Geneva, Switzerland, with offices in Balerna, Offenbach am Main, and Monza, Italy. We are listed on the SIX Swiss Exchange and quoted in the US on OTCQB.